雄激素受体驱动前列腺癌去势抵抗的研究进展

Research progress on castration resistance driven by androgen receptor in prostate cancer

目前内分泌治疗仍然是前列腺癌治疗的基石,但几乎所有前列腺癌患者治疗后均会进展为去势抵抗性前列腺癌。新型内分泌治疗药物已应用于转移性前列腺癌的一线治疗,但仍无法避免耐药。探索雄激素受体在内分泌治疗耐药过程中的作用机制,是破解前列腺癌耐药难题的关键。本文概述近年来雄激素受体耐药调控机制及耐药后治疗策略选择的相关研究进展。

Androgen deprivation therapy is the basic therapy for the treatment of prostate cancer,however,most patients will progress to castration-resistant prostate cancer(CRPC)after therapy.Although abiraterone and enzalutamide are used for the first-line therapy for metastatic prostate cancer,drug resistance is still unavoidable.Gaining further insight into the role of androgen receptor would be critical to decipher the puzzle of therapy resistance.Current research on resistance mechanisms to androgen receptor inhibitors and treatment strategies after resistance were reviewed.